Physician profile
Boris Gliner
NPI 1982648507
$4,560.30
in general payments reported to CMS, 2019-2025
35 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,172 · 2020: $360 · 2021: $260 · 2022: $686 · 2023: $629 · 2024: $971 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,081.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $463.75 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $430.53 | 2019-2024 | Lokelma, Airsupra, Farxiga |
| Phathom Pharmaceuticals, INC. | $390.51 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $347.49 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $301.07 | 2019-2024 | Spravato |
| Novo Nordisk INC | $269.72 | 2019-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $243.04 | 2022 | |
| Amgen INC. | $212.66 | 2019-2025 | Evenity, Repatha |
| Teva Pharmaceuticals USA, INC. | $169.48 | 2019 | |
| Glaxosmithkline, LLC. | $165.35 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $142.01 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Pfizer INC. | $140.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.95 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $131.70 | 2019 | |
| Esperion Therapeutics, INC. | $115.96 | 2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $102.32 | 2020-2025 | Arikayce |
| Biohaven Pharmaceuticals, INC. | $95.30 | 2021 | |
| Coloplast Corp | $87.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.25 | 2019-2025 | Jardiance |
| Abbvie INC. | $78.88 | 2020-2024 | |
| Arbor Pharmaceuticals, INC. | $75.33 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $51.28 | 2019-2023 | Ryaltris |
| Dexcom, INC. | $50.91 | 2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $45.86 | 2023-2024 | Edarbyclor, Edarbyclor |
| Allergan, INC. | $35.41 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $34.51 | 2019 | |
| Abbott Laboratories | $30.07 | 2024-2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $24.72 | 2025 | Yupelri |
| Aimmune Therapeutics, INC. | $20.16 | 2025 | Zenpep |
| Mannkind Corporation | $18.98 | 2025 | |
| Merck Sharp & Dohme LLC | $15.88 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.89 | 2019 | |
| Shire North American Group INC | $14.33 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.97 | 2023 | Rebyota |
| Astellas Pharma US INC | $11.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Gliner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.